Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612538 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Ross J Turner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia. Hauptthemen laut MEDLINE: Papillomavirus Infections, Head and Neck Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Molecular Horizons (University of Wollongong), Illawarra Health and Medical Research Institute, Radiation Oncology Trust Fund (Illawarra Cancer Care Centre, Wollongong).
Abstract (Originalsprache)
The ectonucleotidases CD39 and CD73 are present on immune cells and play important roles in cancer progression by suppressing antitumour immunity. As such, CD39 and CD73 on peripheral blood mononuclear cells (PBMCs) are emerging as potential biomarkers to predict disease outcomes and treatment responses in cancer patients. This study aimed to examine T and B cells, including CD39 and CD73 expressing subsets, by flow cytometry in PBMCs from 28 patients with head and neck squamous cell carcinoma (HNSCC) and to assess the correlation with the treatment modality, human papillomavirus (HPV) status, and relapse-free survival (RFS). The PBMCs were examined pre-, mid-, and post-radiotherapy with concurrent cisplatin chemotherapy or anti-epidermal growth factor receptor antibody (cetuximab) therapy. Combination radiotherapy caused changes to T and B cell populations, including CD39 and CD73 expressing subsets, but no such differences were observed between concurrent chemotherapy and cetuximab. Pretreatment PBMCs from HPV+ patients contained increased proportions of CD39−CD73−CD4+ T cells and reduced proportions of CD39−/+CD73+CD4+ T cells compared to the equivalent cells from HPV− patients. Notably, the pretreatment CD4+:CD8+ T cell ratios and CD39+CD73+CD19+ B cell proportions below the respective cohort medians corresponded with an improved RFS. Collectively, this study supports the notion that CD39 and CD73 may contribute to disease outcomes in HNSCC patients and may assist as biomarkers, either alone or as part of immune signatures, in HNSCC. Further studies of CD39 and CD73 on PBMCs from larger cohorts of HNSCC patients are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia.
- Illawarra Health and Medical Research Institute, Wollongong, NSW 2522, Australia.
- Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, NSW 2500, Australia.
- Graduate School of Medicine, University of Wollongong, Wollongong, NSW 2522, Australia.
- GenesisCare, St Vincent's Clinic, Darlinghurst, NSW 2010, Australia.
ORCID-Profile: Nicholas J Geraghty, Ashleigh Splitt, Ronald Sluyter
Förderung
- Molecular Horizons (University of Wollongong)
- Illawarra Health and Medical Research Institute
- Radiation Oncology Trust Fund (Illawarra Cancer Care Centre, Wollongong)
- MDPI
Zitieren
APA
Turner, R. J., Guy, T. V., Geraghty, N. J., Splitt, A., Watson, D., Brungs, D., Carolan, M. G., Miller, A. A., de Leon, J. F., Aghmesheh, M., & Sluyter, R. (2023). Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612538
Vancouver
Turner RJ, Guy TV, Geraghty NJ, Splitt A, Watson D, Brungs D, et al. Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612538
BibTeX
@article{Turner2023,
author = {Turner, Ross J and Guy, Thomas V and Geraghty, Nicholas J and Splitt, Ashleigh and Watson, Debbie and Brungs, Daniel and Carolan, Martin G and Miller, Andrew A and de Leon, Jeremiah F and Aghmesheh, Morteza and Sluyter, Ronald},
title = {Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612538}
}
EUVIMED